Clinical trial
Iressa 2nd Line Phase III Study in Japan
NCT00252707 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00252707 |
|---|---|
| Title | Iressa 2nd Line Phase III Study in Japan |
| Official title | A Multicentre, Randomised, Open-Label, Parallel-Group, Phase III Post-Marketing Clinical Study to Compare the Overall Survival Between Gefitinib and Docetaxel in Patients With Advanced or Metastatic (Stage IIIB/IV), or Recurrent Non-Small Cell Lung Cancer, Who Have Failed One or Two Chemotherapy… |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Gefitinib or Docetaxel |
| Enrollment | 484 |
| Start date | Sep 1, 2003 |
| Completion | Nov 1, 2006 |
| First posted | Nov 15, 2005 |
| Last update posted | Dec 18, 2007 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: